The FDA is undertaking initiatives to make its decision-making process more transparent as a means to regaining public trust and confidence in the agency, FDA Commissioner Margaret Hamburg said in an interview. The agency also needs to develop a more streamlined regulatory process for drugs and other medical products to include the application of biomarkers and test-animal models, Hamburg said.

Full Story:

Related Summaries